19 results
8-K
EX-99.1
COYA
Coya Therapeutics Inc
9 May 24
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
4:20pm
Financial Results
As of March 31, 2024, Coya had cash and cash equivalents of $36.0 million.
Research and development (R&D) expenses were $3.1 million
8-K
EX-99.1
COYA
Coya Therapeutics Inc
19 Mar 24
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
8:21am
an additional $7.5 million in January from Dr. Reddy’s as an upfront payment as part of the COYA 302 licensing arrangement.
Research and development (R&D) expenses
8-K
EX-99.1
4s19s042uk jjde
8 Nov 23
Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results
9:03am
8-K
EX-99.1
orxrmm19
8 Aug 23
Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results
7:05am
DEF 14A
8vhdhb7e o26vzb
19 May 23
Definitive proxy
4:31pm
8-K
EX-99.2
i2xrlwm gkyz1ofs37v
16 May 23
Regulation FD Disclosure
7:47am
8-K
EX-99.1
pp1avwm4
10 May 23
Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial Results
7:11am
424B4
6zcj4d9
30 Dec 22
Prospectus supplement with pricing info
4:17pm
S-1/A
zz16bmu ojffe200eu
5 Dec 22
IPO registration (amended)
8:16am
S-1
slofni gwdoed870
18 Nov 22
IPO registration
5:06pm
DRS/A
ctntdq1m9v8x
28 Oct 22
Draft registration statement (amended)
12:00am
DRSLTR
65qsoz
7 Oct 22
Correspondence regarding draft registration statement
12:00am
DRS/A
v7e2teak
7 Oct 22
Draft registration statement (amended)
12:00am
DRS
g6dwzqd1
19 Aug 22
Draft registration statement
12:00am
- Prev
- 1
- Next